GLP-1 Pipeline In November 2023, the FDA approved Zepbound (tirzepatide), a GLP-1 antagonist and GIP dual agonist with superior weight loss efficacy compared to its competitors
Common injection sites include: Abdomen Thighs Upper arms Flow Wellness recommends rotating among approved injection sites to help reduce irritation and improve comfort
The small step of this goal makes it realistic and achievable, Oshita explains
Acetaminophen does not irritate the stomach or significantly affect kidney blood flow, making it safer than NSAIDs for most tirzepatide patients
Nutrient IM injections are physician-supervised treatments
The most common side effects are mild nausea, constipation, and stomach discomfort, especially during the first few weeks as your body adjusts